Abstract:Abstract 3092 Desmoplastic small round cell tumor of the peritoneum (DSRCTP) is a rare, frequently fatal solid tumor that occurs most commonly in adolescent males. Tumor characteristics were first described in 1989 and the largest review of 101 patients in 1996 demonstrated a median survival of 17 months (range 3–72) in patients with a median age of 21 years (range 6–38), none of whom underwent transplant. Survivorship has improved with the use of intensive alkylator regimens and incorporation of autologous stem cell transplant (ASCT). This study represents the largest reported cohort of patients with DSRCTP who have undergone ASCT. Increasingly aggressive chemotherapy regimens and ASCT have been used to try to prolong response and increase cure. The purpose of this study was to examine the outcomes in the largest reported cohort of patients with DSRCTP who have undergone ASCT. We identified 36 patients with DSRCTP reported to the Center for International Blood and Marrow Transplant Research between 1999 and 2007 who received an autologous hematopoietic stem cell transplant. The median age was 19 years (range 8–46) and 29 (81%) were male. Pre-transplant disease status was known in 31 patients, 13 of whom were in complete remission (CR). Twenty different conditioning regimens were identified for the 30 patients on which data was available with the most common agents being thiotepa (19 patients), etoposide (12 patients), mephalan (12 patients), cyclophosphamide (9 patients) and carboplatin (8 patients). The median follow up was 44 months. A subset of 18 patients had supplemental information obtained for confirmation of diagnosis (verification of the presence of translocation: t(11;22)(p13;q12)) and expanded clinical detail. We performed descriptive statistics to characterize the patients and outcomes. The probability of disease free survival (DFS) at one year for those patients in CR and not in CR was 75% (95% CI: 48–94%) and 35% (15–59%), respectively. For the entire cohort, 1 year DFS was 53% (39–69%). DFS at 3 years was 40% (15–69%) and 9% (0–29%) in the two groups, respectively. The probability of overall survival at three years was 57% (29–83%) for patients in CR and 28% (9–51%) for patients not in CR. Median survival for the entire cohort was 31 months (36 months for those in CR, 21 months for those not in CR). Treatment related mortality was low with only 1 death in the first 100 days. Engraftment at 42 days was 97% (88–100%). In summary, ASCT appears to be a tolerable approach in patients with DSCRTP with the greatest benefit seen in those patients who obtain CR. High intensity chemotherapy and ASCT leads to the longest DFS and OS in those patients who obtain a CR pre-transplant as might be expected. For those not in CR, the median OS in this series is greater (21 months) than previously reported (17 months) in patients not treated with ASCT suggesting a potential role for ASCT to prolong DFS and OS even in patients with residual or persistent disease pre-transplant. Overall, with low treatment related mortality and prolonged survival compared to historical controls, ASCT is a reasonable option for patients with DSRCTP though its role should be confirmed in larger studies. Disclosures: No relevant conflicts of interest to declare.

The Role of High Dose Chemotherapy with Autologous Hematopoietic Cell Transplant in Relapsed/Refractory Ovarian Germ Cell Tumors: A Single Center Experience

High-Dose Chemotherapy and Autologous Stem Cell Transplantation Outcomes—A Single-Centre Experience

High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Salvage Therapy of Relapsed/Refractory Germ Cell Tumors: A Single-Center Experience

High-dose chemotherapy with autologous stem cell transplants in adult primary non-seminoma mediastinal germ-cell tumors. A report from the Cellular Therapy and Immunobiology working party of the EBMT

Therapeutic efficacy of high-dose chemotherapy with autologous stem-cell transplantation in 44 relapsed or refractory germ-cell tumor patients: A retrospective cohort study

High doses of chemotherapy and autologous hematopoietic stem cell transplantation in patients with relapsed/refractory testicular germ cell tumors: Multicenter real-world experience in Argentina.

Efficacy and safety of high-dose chemotherapy as the first or subsequent salvage treatment line in patients with relapsed or refractory germ cell cancer: an international multicentric analysis

Outcomes of relapsed/refractory extracranial germ cell tumors treated on conventional salvage chemotherapy without stem cell rescue: Experience from a tertiary cancer center

Australia and New Zealand (ANZ) outcomes of high-dose chemotherapy and stem cell transplantation for relapsed or refractory germ cell tumors (GCT) from 1999 to 2019: Multicenter registry-based study with ABMTRR.

High‐dose chemotherapy and peripheral blood stem cell transplantation as salvage therapy in primary mediastinal nonseminomatous germ cell tumors: The Indiana University experience

Is There a Role for ASCT in Patients with Desmoplastic Small Round Cell Tumor of the Peritoneum?

High-dose chemotherapy and autologous stem cell transplantation for primary central nervous system lymphoma: a multi-centre retrospective analysis from the United Kingdom

The status of high-dose chemotherapy with hematopoietic stem cell transplantation in germ cell tumor patients

High-dose chemotherapy as initial salvage chemotherapy in patients with relapsed or refractory testicular cancer: a systematic review and meta-analysis

Impact of Optimal Therapy and Prognostic Factors in Malignant Germ Cell Tumors of Ovary: 20 Years' Institutional Experience

The Role of Secondary Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy in Recurrent Ovarian Peritoneal Carcinomatosis

Outcomes of Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma Receiving Salvage Cytotoxic Therapy with Supportive Stem Cell Boost

Therapy Response and Survival among Patients with Gynecologic Tumors Treated with Transarterial Chemoperfusion and Transarterial Chemoembolization

Efficacy of Gemcitabine, Paclitaxel, and Oxaliplatin Protocol in the Treatment of Relapsed or Refractory Germ Cell Tumours

Outcomes and prognostic variables of extracranial germ cell tumors in children and adolescents treated over a decade: A developing world perspective

Clinical outcome and prognostic factors for immunotherapy-based treatments in patients with platinum-refractory germ cell tumor